AzTrials
AzTrials

Overactive Bladder SyndromePhase 3NCT00546637

Fesoterodine "add-on" Male Overactive Bladder Study

A Phase 3 study testing Fesoterodine in people with Overactive Bladder Syndrome, run by Pfizer at 137 sites in 19 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

To evaluate the efficacy and safety of fesoterodine on overactive bladder symptom improvement when added to ongoing alpha blocker treatment. Read more about this study

Who is it for?
Ages 40 years and older, men only
Conditions the study is for
Overactive Bladder Syndrome
What is being tested?
Fesoterodine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
947 participants
Where
137 sitesin 19 countries
Study dates
Nov 2007to Feb 2009
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 40 years and older
  • Men only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Men aged 40 years and above.
  • On a stable and well-tolerated dose of an alpha-blocker prescribed for LUTS for at least 6 weeks prior to screening (Visit 1).
  • Persistent symptoms of OAB with urinary frequency >=8 times/24 hours and micturition-related urgency episodes >=3 episode/24 hours.

Who cannot join

  • Contraindication to fesoterodine (antimuscarinics).
  • Previous history of acute urinary retention requiring catheterization or severe voiding difficulties in the judgment of the investigator, prior to baseline.
  • Unable to follow the study procedures, including completion of self-administered bladder diary and patient reported outcome questionnaires.

Trial locations and contacts

137 sites in 19 countries.

137 sites in 19 countries

United States62 sites
  • Pfizer Investigational Site

    Albany, New York, 12208

  • Pfizer Investigational Site

    Aurora, Colorado, 80012

  • Pfizer Investigational Site

    Austin, Texas, 78705

  • Pfizer Investigational Site

    Austin, Texas, 78759

  • Pfizer Investigational Site

    Bala-Cynwyd, Pennsylvania, 19004

  • Pfizer Investigational Site

    Baltimore, Maryland, 21204

  • Pfizer Investigational Site

    Bethany, Oklahoma, 73008

  • Pfizer Investigational Site

    Birmingham, Alabama, 35209

  • Pfizer Investigational Site

    Camp Hill, Pennsylvania, 17011

  • Pfizer Investigational Site

    Charleston, South Carolina, 29425

  • Pfizer Investigational Site

    Cincinnati, Ohio, 45242

  • Pfizer Investigational Site

    Columbus, Ohio, 43214

  • Pfizer Investigational Site

    Columbus, Ohio, 43220

  • Pfizer Investigational Site

    Denver, Colorado, 80211

  • Pfizer Investigational Site

    Des Moines, Iowa, 50309

  • Pfizer Investigational Site

    Dunwoody, Georgia, 30338

  • Pfizer Investigational Site

    Durham, North Carolina, 27710

  • Pfizer Investigational Site

    Evansville, Indiana, 47713

  • Pfizer Investigational Site

    Fargo, North Dakota, 58103

  • Pfizer Investigational Site

    Fargo, North Dakota, 58104

  • Pfizer Investigational Site

    Flint, Michigan, 48507

  • Pfizer Investigational Site

    Garden City, New York, 11530

  • Pfizer Investigational Site

    Gilbert, Arizona, 85234

  • Pfizer Investigational Site

    Gilbert, Arizona, 85295

  • Pfizer Investigational Site

    Greensboro, North Carolina, 27403

  • Pfizer Investigational Site

    Greer, South Carolina, 29650

  • Pfizer Investigational Site

    Houston, Texas, 77024

  • Pfizer Investigational Site

    Iowa City, Iowa, 52242

  • Pfizer Investigational Site

    Jeffersonville, Indiana, 47130

  • Pfizer Investigational Site

    Jupiter, Florida, 33458

  • Pfizer Investigational Site

    Kingston, New York, 12401

  • Pfizer Investigational Site

    La Mesa, California, 91942

  • Pfizer Investigational Site

    Litchfield Park, Arizona, 85340

  • Pfizer Investigational Site

    Madison, Wisconsin, 53715

  • Pfizer Investigational Site

    Mesa, Arizona, 85210

  • Pfizer Investigational Site

    Milwaukee, Wisconsin, 53209

  • Pfizer Investigational Site

    Minneapolis, Minnesota, 55455

  • Pfizer Investigational Site

    New York, New York, 10016

  • Pfizer Investigational Site

    Newburgh, Indiana, 47630

  • Pfizer Investigational Site

    Newport Beach, California, 92660

  • Pfizer Investigational Site

    Omaha, Nebraska, 68114

  • Pfizer Investigational Site

    Orange City, Florida, 32763

  • Pfizer Investigational Site

    Owings Mills, Maryland, 21117

  • Pfizer Investigational Site

    Phoenix, Arizona, 85021

  • Pfizer Investigational Site

    Pittsburgh, Pennsylvania, 15213

  • Pfizer Investigational Site

    Portland, Oregon, 97239

  • Pfizer Investigational Site

    Poughkeepsie, New York, 12601

  • Pfizer Investigational Site

    Saint Clair Shores, Michigan, 48081

  • Pfizer Investigational Site

    San Bernardino, California, 92404

  • Pfizer Investigational Site

    San Diego, California, 92103-6204

  • Pfizer Investigational Site

    San Diego, California, 92103

  • Pfizer Investigational Site

    Sewell, New Jersey, 08080

  • Pfizer Investigational Site

    Syracuse, New York, 13210

  • Pfizer Investigational Site

    Tacoma, Washington, 98431-1100

  • Pfizer Investigational Site

    Troy, Michigan, 48084

  • Pfizer Investigational Site

    Tucson, Arizona, 85712

  • Pfizer Investigational Site

    Utica, Michigan, 48081

  • Pfizer Investigational Site

    Watertown, Massachusetts, 02472

  • Pfizer Investigational Site

    West Bloomfield, Michigan, 48322

  • Pfizer Investigational Site

    West Bloomfield, Michigan, 48323

  • Pfizer Investigational Site

    West Palm Beach, Florida, 33401

  • Pfizer Investigational Site

    Williamsville, New York, 14221

Other trials in United States

Canada9 sites
  • Pfizer Investigational Site

    Barrie, Ontario, L4M 7G1

  • Pfizer Investigational Site

    Chicoutimi, Quebec, G7H 4A3

  • Pfizer Investigational Site

    North Bay, Ontario, P1B 7K8

  • Pfizer Investigational Site

    Pointe-Claire, Quebec, H9R 4S3

  • Pfizer Investigational Site

    Sherbrooke, Quebec, J1H 5N4

  • Pfizer Investigational Site

    Toronto, Ontario, M5T 2S8

  • Pfizer Investigational Site

    Toronto, Ontario, M6A 3B5

  • Pfizer Investigational Site

    Victoria, British Columbia, V8T 5G1

  • Pfizer Investigational Site

    Winnipeg, Manitoba, R3A 1R9

Other trials in Canada

Germany8 sites
  • Pfizer Investigational Site

    Berlin, 12627

  • Pfizer Investigational Site

    Frankfurt, 60596

  • Pfizer Investigational Site

    Göttingen, 37073

  • Pfizer Investigational Site

    Hagenow, 19230

  • Pfizer Investigational Site

    Lauenburg, 21481

  • Pfizer Investigational Site

    Leipzig, 04109

  • Pfizer Investigational Site

    Oberursel, 61440

  • Pfizer Investigational Site

    Wiesbaden, 65198

Other trials in Germany

Brazil6 sites
  • Pfizer Investigational Site

    Campos do Jordão, São Paulo, 12460-000

  • Pfizer Investigational Site

    Curitiba, Paraná, 80060-900

  • Pfizer Investigational Site

    Porto Alegre, Rio Grande do Sul, 90610-000

  • Pfizer Investigational Site

    Rio de Janeiro, Rio de Janeiro, CEP 20551-030

  • Pfizer Investigational Site

    Salvador, Estado de Bahia, 40420-000

  • Pfizer Investigational Site

    São Paulo, São Paulo, 04262-000

Other trials in Brazil

Philippines6 sites
  • Pfizer Investigational Site

    Bacolod City, 6100

  • Pfizer Investigational Site

    Cebu City, Cebu, 6000

  • Pfizer Investigational Site

    Makati City, 1200

  • Pfizer Investigational Site

    Manila, 1000

  • Pfizer Investigational Site

    Manila, 1008

  • Pfizer Investigational Site

    Quezon City, Philippines, 1113

Other trials in Philippines

Poland6 sites
  • Pfizer Investigational Site

    Bialystok, 15-232

  • Pfizer Investigational Site

    Gdansk, 80-402

  • Pfizer Investigational Site

    Gdansk, 80-462

  • Pfizer Investigational Site

    Lodz, 93-338

  • Pfizer Investigational Site

    Mysłowice, 41-400

  • Pfizer Investigational Site

    Wroclaw, 51-124

Other trials in Poland

Slovakia5 sites
  • Pfizer Investigational Site

    Banská Bystrica, 974 01

  • Pfizer Investigational Site

    Bratislava, Slovakia, 833 05

  • Pfizer Investigational Site

    Martin, Slovakia, 036 59

  • Pfizer Investigational Site

    Piešťany, Slovakia, 921 01

  • Pfizer Investigational Site

    Skalica, 909 82

Other trials in Slovakia

Sweden5 sites
  • Pfizer Investigational Site

    Borås, 503 32

  • Pfizer Investigational Site

    Jönköping, 554 66

  • Pfizer Investigational Site

    Skövde, 541 30

  • Pfizer Investigational Site

    Stockholm, 117 94

  • Pfizer Investigational Site

    Stockholm, 141 86

Other trials in Sweden

India4 sites
  • Pfizer Investigational Site

    Lucknow, Uttar Pradesh, 226003

  • Pfizer Investigational Site

    Lucknow, Uttar Pradesh, 226014

  • Pfizer Investigational Site

    Ludhiana, Punjab, 141008

  • Pfizer Investigational Site

    New Delhi, New Delhi, 110029

Other trials in India

South Korea4 sites
  • Pfizer Investigational Site

    Bucheon-si, Gyunggi-do, 420-717

  • Pfizer Investigational Site

    Pusan, 602-739

  • Pfizer Investigational Site

    Seoul, 135-710

  • Pfizer Investigational Site

    Seoul, 135-720

Other trials in South Korea

Belgium3 sites
  • Pfizer Investigational Site

    Antwerp, 2020

  • Pfizer Investigational Site

    Edegem, B-2650

  • Pfizer Investigational Site

    Leuven, B-3000

Other trials in Belgium

Greece3 sites
  • Pfizer Investigational Site

    Ioannina, Ipiros, 45 110

  • Pfizer Investigational Site

    Pátrai, 26500

  • Pfizer Investigational Site

    Thessaloniki, 56403

Other trials in Greece

Netherlands3 sites
  • Pfizer Investigational Site

    Roermond, 6043 CV

  • Pfizer Investigational Site

    Tilburg, 5022 GC

  • Pfizer Investigational Site

    Zutphen, 7207 BA

Other trials in Netherlands

Spain3 sites
  • Pfizer Investigational Site

    Getafe, Madrid, 28905

  • Pfizer Investigational Site

    Manacor, Palma de Mallorca, 07500

  • Pfizer Investigational Site

    Martorell, Barcelona, 08760

Other trials in Spain

Colombia2 sites
  • Pfizer Investigational Site

    Bogota, Cundinamarca, 0000

  • Pfizer Investigational Site

    Medellín, Antioquia, 0000

Other trials in Colombia

Malaysia2 sites
  • Pfizer Investigational Site

    Kuching, Sarawak, 93050

  • Pfizer Investigational Site

    Kuching, Sarawak, 93586

Other trials in Malaysia

Norway2 sites
  • Pfizer Investigational Site

    Bodø, 8087

  • Pfizer Investigational Site

    Oslo, NO-0257

Other trials in Norway

Singapore2 sites
  • Pfizer Investigational Site

    Singapore, Singapore, 169608

  • Pfizer Investigational Site

    Singapore, Singapore, 308433

Other trials in Singapore

Thailand2 sites
  • Pfizer Investigational Site

    Amphoe Mueang, Chiang Mai, 50200

  • Pfizer Investigational Site

    Ratchathewi, Bangkok, 10400

Other trials in Thailand

About this study

Official title: A Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Fesoterodine As An "Add-On" Therapy In Men With Persistent Overactive Bladder Symptoms Under Monotherapy Of Alpha Blocker For Lower Urinary Tract Symptoms.

To evaluate the efficacy and safety of fesoterodine on overactive bladder symptom improvement when added to ongoing alpha blocker treatment.

Being tested
Fesoterodine, Placebo

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • FesoterodineDrug

    Fesoterodine 4mg or 8mg

  • PlaceboDrug

    Placebo

Study groups in NCT00546637
Study groupRoleWhat they receive
Fesoterodine 4mg or 8mgExperimentalNot described
Receives: Drug: Fesoterodine
PlaceboPlacebo comparatorNot described
Receives: Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Numerical Change From Baseline in Micturition-Related Urgency Episodes Per 24 Hours at Week 12

    The mean number of micturition-related urgency episodes per 24 hours was calculated as the total number of micturitions with USS Scale >= 3 divided by the total number of days that diary data was collected at that visit. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.

    Measured: Baseline, Week 12

Secondary outcomes (33)
  1. Numerical Change From Baseline in Micturition-Related Urgency Episodes Per 24 Hours at Week 4

    The mean number of micturition-related urgency episodes per 24 hours was calculated as the total number of micturitions with USS Scale >= 3 divided by the total number of days that diary data was collected at that visit. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.

    Measured: Baseline, Week 4

  2. Percentage Change From Baseline in Micturition-Related Urgency Episodes Per 24 Hours at Week 4 and 12

    Micturition-related urgency episodes per 24 hours were defined as those with USS Scale rating of >= 3 marked for the corresponding micturition in the diary. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine. The percentage change at Week 4 or 12 was calculated as:

    100* (Micturition-Related Urgency Episodes at Week 4 or 12 - Baseline)/Baseline

    Measured: Baseline, Week 4 and 12

  3. Numerical Change From Baseline in Micturitions Per 24 Hours at Week 4 and 12

    All micturitions with USS rating 1 to 5. USS rating: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine. The mean number of micturitions per 24 hours was calculated as the total number of micturitions divided by the total number of diary days collected at that visit. Numeric change of micturitions per 24 hours at Week 4 and 12 relative to Baseline.

    Measured: Baseline, Week 4 and 12

  4. Percentage Change From Baseline in Micturitions Per 24 Hours at Week 4 and 12

    All micturitions with USS rating 1 to 5. USS rating: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine. The percentage change at Week 4 or 12 was calculated as: 100* (Micturitions at Week 4 or 12 - Baseline)/Baseline

    Measured: Baseline, Week 4 and 12

  5. Numerical Change From Baseline in Nocturnal Micturitions Per 24 Hours at Week 4 and 12

    Nocturnal micturitions were defined as micturitions with USS rating 1-5 that occurred between the time the subject went to bed and the time he or she arose to start the next day. USS rating: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine. The mean number of nocturnal micturitions per 24 hours was calculated as the total number of nocturnal micturitions divided by the total number of diary days collected at that visit.

    Measured: Baseline, Week 4 and 12

  6. Percentage Change From Baseline in Nocturnal Micturitions Per 24 Hours at Week 4 and 12

    Nocturnal micturitions were defined as micturitions with USS rating 1-5 that occurred between the time the subject went to bed and the time he or she arose to start the next day. USS rating: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine. The percentage change at Week 4 or 12 was calculated as: 100* (Nocturnal micturitions at Week 4 or 12 - Baseline)/Baseline

    Measured: Baseline, Week 4 and 12

  7. Numerical Change From Baseline in Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 4 and 12

    UUI episodes were defined as those micturitions with USS rating of 5 in the diary in subjects with UUI at baseline. USS rating 5: Unable to hold; leak urine.

    Measured: Baseline, Week 4 and Week 12

  8. Percentage Change From Baseline in UUI Episodes Per 24 Hours at Week 4 and 12

    UUI episodes are defined as those micturitions with a USS rating of 5 in the bladder diary in subjects with UUI at baseline. USS rating 5: Unable to hold; leak urine. The percentage change at Week 4 or 12 was calculated as: 100* (UUI Episodes at Week 4 or 12 - Baseline)/Baseline

    Measured: Baseline, Week 4 and 12

  9. Numerical Change From Baseline in Severe Micturition-Related Urgency Episodes Per 24 Hours at Week 4 and 12

    Severe micturition related urgency episodes were defined as those micturitions with USS rating >=4 marked for the corresponding micturition in the diary. USS: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.

    Measured: Baseline, Week 4 and 12

  10. Percentage Change From Baseline in Severe Micturition-Related Urgency Episodes Per 24 Hours at Week 4 and 12

    Severe micturition-related urgency episodes are defined as those with a USS rating ≥4 marked for the corresponding micturition in the bladder diary. USS rating: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine. The percentage change at Week 4 or 12 was calculated as: 100* (Severe Micturition-Related Urgency Episodes at Week 4 or 12 - Baseline)/Baseline

    Measured: Baseline, Week 4 and 12

  11. Numerical Change From Baseline in Nocturnal Micturition-Related Urgency Episodes Per 24 Hours at Week 4 and 12

    Nocturnal micturition-related urgency episodes were defined as micturition-related urgency episodes with USS ratings 3-5 that occurred between the time the subject went to bed and the time he or she arose to start the next day. USS rating: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.

    Measured: Baseline, Week 4 and 12

  12. Percentage Change From Baseline in Nocturnal Micturition-Related Urgency Episodes Per 24 Hours at Week 4 and 12

    Nocturnal micturition-related urgency episodes were defined as micturition-related urgency episodes with USS ratings 3-5 that occurred between the time the subject went to bed and the time he or she arose to start the next day. USS rating: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine. The percentage change at Week 4 or 12 was calculated as: 100* (Nocturnal Micturition-Related Urgency Episodes at Week 4 or 12 - Baseline)/Baseline

    Measured: Baseline, Week 4 and 12

  13. Numerical Change From Baseline in Urinary Sensation Scale (USS) Sum Rating Per 24 Hours at Week 4 and 12

    The USS sum rating was defined as the total of USS ratings recorded for all micturitions over the course of a day in the bladder diary. USS rating: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine. USS Sum rating per 24 hours was calculated as the mean rating scores on the USS multiplied by the mean number of micturitions per 24 hours at that visit.

    Measured: Baseline, Week 4 and 12

  14. Change From Baseline in International Prostate Symptom Score (IPSS) Total Score (Sum Question 1 [Q1] to Q7) Per 24 Hours at Week 4 and 12

    The IPSS Total Score is obtained by combining the scores of the responses to 1 though 7 component questions. Each question is scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms.

    Measured: Baseline, Week 4 and 12

  15. Change From Baseline in IPSS Storage Domain (Sum Q2, Q4, and Q7) Per 24 Hours at Week 4 and 12

    The IPSS Total Score is obtained by combining the scores of the responses to 1 though 7 component questions. Each question is scored from 0-5. Total IPSS range = 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Sum of Q2, Q4, and Q7 range = 0-15 points.

    Measured: Baseline, Week 4 and 12

  16. Change From Baseline in IPSS Voiding Domain (Sum Q1, Q3, Q5, and Q6) Per 24 Hours at Week 4 and 12

    The IPSS Total Score is obtained by combining the scores of the responses to 1 though 7 component questions. Each question is scored from 0-5. Total IPSS range = 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Sum of Q1, Q3, Q5, and Q6 range = 0-20 points.

    Measured: Baseline, Week 4 and 12

  17. Change From Baseline in IPSS Quality of Life (QoL) Score (Q8) Per 24 Hours at Week 4 and 12

    The IPSS Total Score is obtained by combining the scores of the responses to 1 though 7 component questions. Each question is scored from 0-5. Total IPSS range = 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Score of Q8 range = 0-5 points.

    Measured: Baseline, Week 4 and 12

  18. Change From Baseline in IPSS Individual Item Scores (Q1, Q2, Q3, Q4, Q5, Q6, and Q7) Per 24 Hours at Week 4

    The IPSS Total Score is obtained by combining the scores of the responses to 1 though 7 component questions. Each question is scored from 0-5. Total IPSS range = 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms.

    Measured: Baseline, Week 4

  19. Change From Baseline in IPSS Individual Item Scores (Q1, Q2,Q3, Q4, Q5, Q6, and Q7) Per 24 Hours at Week 12

    The IPSS Total Score is obtained by combining the scores of the responses to 1 though 7 component questions. Each question is scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms.

    Measured: Baseline, Week 12

  20. Number of Participants With Change From Baseline in Patient Perception of Bladder Condition (PPBC) Per 24 Hours at Week 4

    PPBC: self-administered, single-item, validated questionnaire. Rated on a 6-point scale: subject was asked: "Which of the following statements describes your bladder condition best at the moment?" 1=no problems at all; 2=some very minor problems; 3=some minor problems; 4=some moderate problems; 5=severe problems; 6=many severe problems. A post-baseline vs baseline variable with ordinal values was derived: 1=Deterioration=Difference in scores was positive; 2=No Change=Difference in scores was 0; 3=Minor Improvement=Difference in scores was -1; 4=Major Improvement=Difference in scores was ≤ 2.

    Measured: Baseline, Week 4

  21. Number of Participants With Change From Baseline in PPBC Per 24 Hours at Week 12

    PPBC: self-administered, single-item, validated questionnaire. Rated on a 6-point scale: subject was asked: "Which of the following statements describes your bladder condition best at the moment?" 1=no problems at all; 2=some very minor problems; 3=some minor problems; 4=some moderate problems; 5=severe problems; 6=many severe problems. A post-baseline vs baseline variable with ordinal values was derived: 1=Deterioration=Difference in scores was positive; 2=No Change=Difference in scores was 0; 3=Minor Improvement=Difference in scores was -1; 4=Major Improvement=Difference in scores was ≤ 2.

    Measured: Baseline, Week 12

  22. Number of Participants With Change From Baseline in Urgency Perception Scale (UPS) Per 24 Hours at Week 4

    Number of participants in 3-point category: improvement [>=1-point improvement]; no change; deterioration [>=1-point decrease], based on UPS score (rated on 3-point scale: 1=not able to hold urine; 3=able to finish what I am doing). Score change calculated as score at observation minus score at baseline; re-scaled to 3-point categorical variables.

    Measured: Baseline, Week 4

  23. Number of Participants With Change From Baseline in Change From Baseline in UPS Per 24 Hours at Week 12.

    Number of participants in 3-point category: improvement [>=1-point improvement]; no change; deterioration [>=1-point decrease], based on UPS score (rated on 3-point scale: 1=not able to hold urine; 3=able to finish what I am doing). Score change calculated as score at observation minus score at baseline; re-scaled to 3-point categorical variables.

    Measured: Baseline, Week 12

  24. Change From Baseline in Overactive Bladder Questionnaire (OAB-q) Per 24 Hours at Week 4 and 12

    OAB-q is a self-administered, 33-item, validated questionnaire that assesses how much the subject has been bothered by selected bladder symptoms during the previous week. Each item rated by subject on Likert scale 1 (least symptom bother) to 6 (most symptom bother). Raw scores were transformed to a score from 0-100. Once transformed, higher scores represent less favorable outcome.

    Measured: Baseline, Week 4 and 12

  25. Change From Baseline in Total Score of Each Health Related Quality of Life (HRQL) Domain of OAB-q at Week 4 and 12

    HRQL domain and total raw score derived as sum of scores (6-point scale: 1 = not at all/none of the time; 6 = a very great deal/all of the time). Transformed score range 0 to 100 (Total HRQL or domain)=[(Highest possible raw score-Actual total raw score)/Raw score range]x100. Higher transformed scores indicative of better HRQL. Positive change in HRQL scores indicates improvement. Change: score at observation minus score at baseline.

    Measured: Baseline, Week 4 and 12

  26. Change From Baseline in Score of Each Health Related Quality of Life (HRQL) Domain of OAB-q at Week 4 and 12 (OAB-q Concern Domain)

    The HRQL concern domain; range was 0-100. The transformed score for HRQL was calculated based on the following formula: Transformed score (HRQL) = [(Highest possible score - Actual raw score)/ Range]*100, where range was the raw score range. Positive change in HRQL Score indicates improvement.

    Measured: Baseline, Week 4 and 12

  27. Change From Baseline in Score of Each Health Related Quality of Life (HRQL) Domain of OAB-q at Week 4 and 12 (OAB-q Coping Domain)

    The HRQL coping domain; range was 0-100. The transformed score for HRQL was calculated based on the following formula: Transformed score (HRQL) = [(Highest possible score - Actual raw score)/ Range]*100, where range was the raw score range. Positive change in HRQL Score indicates improvement.

    Measured: Baseline, Week 4 and Week 12

  28. Change From Baseline in Score of Each Health Related Quality of Life (HRQL) Domain of OAB-q at Week 4 and 12 (OAB-q Sleep Domain)

    The HRQL sleep domain; range was 0-100. The transformed score for HRQL was calculated based on the following formula: Transformed score (HRQL) = [(Highest possible score - Actual raw score)/ Range]*100, where range was the raw score range. Positive change in HRQL Score indicates improvement.

    Measured: Baseline, Week 4 and Week 12

  29. Change From Baseline in Score of Each Health Related Quality of Life (HRQL) Domain of OAB-q at Week 4 and 12 (OAB-q Social Interaction Domain)

    The HRQL social interaction domain; range was 0-100. The transformed score for HRQL was calculated based on the following formula: Transformed score (HRQL) = [(Highest possible score - Actual raw score)/ Range]*100, where range was the raw score range. Positive change in HRQL Score indicates improvement.

    Measured: Baseline, Week 4 and Week 12

  30. Change From Baseline in Post Void Residual (PVR) Urine Volume Per 24 Hours at Week 4, 8 and 12

    Post-void residual volume measurement was measured by an ultrasound at Baseline, and at Weeks 4, 8 and 12.

    Measured: Baseline, Week 4, 8 and 12

  31. Change From Baseline in Maximum Urinary Flow Rate (QMAX) Per 24 Hours at Week 12

    Maximum urinary flow rate (Qmax) was recorded at Baseline and Week 12 visit.

    Measured: Baseline, Week 12

  32. Number of Participants Reporting Urinary Retention Requiring Catheterization (All Causalities)

    Number of participants experiencing serious and non-serious adverse events of acute urinary retention requiring catheterization.

    Measured: Baseline, Week 12

  33. Number of Participants Experiencing Adverse Events Related to Increased Voiding Difficulty (All Causalities)

    Number of participants experiencing serious and non-serious adverse events related to increased voiding difficulty (ie, Dysuria, Urinary retention regardless of catheterization, Urine flow decreased, Residual urine volume, Residual urine volume increased, Residual urine, and Urinary hesitation)

    Measured: Baseline, Week 12

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Oct 2007 (estimated)
  2. Study startNov 2007
  3. Primary completionFeb 2009
  4. Study completionFeb 2009

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
947 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00546637
Sponsor's protocol ID
A0221009
Status last verified
Feb 2011
First submitted
18 Oct 2007
Last updated
18 Feb 2011

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Fesoterodine in people with Overactive Bladder Syndrome, run by Pfizer at 137 sites in 19 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 18 Feb 2011. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 137 sites in United States, Canada, Germany, Brazil, Philippines and 14 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 22 Nov 2010). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Numerical Change From Baseline in Micturition-Related Urgency Episodes Per 24 Hours at Week 12 (time frame: Baseline, Week 12). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Feb 2011.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in